Richa Poddar's most recent trade in Agios Pharmaceuticals Inc was a trade of 5,000 Restricted stock units done . Disclosure was reported to the exchange on Oct. 15, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2022 | 5,000 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2022 | 5,000 | 9,993 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.48 per share. | 15 Oct 2022 | 1,485 | 8,508 (0%) | 0% | 27.5 | 40,808 | Common stock |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 41,000 | 41,000 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,500 | 11,500 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 1,884 | 1,883 | - | - | Performance share units | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 1,884 | 4,525 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 18 Feb 2022 | 742 | 4,441 (0%) | 0% | 29.1 | 21,577 | Common stock |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 658 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 658 | 5,183 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 1,738 | 1,738 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 1,738 | 3,231 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.50 per share. | 14 Feb 2022 | 590 | 2,641 (0%) | 0% | 30.5 | 17,995 | Common stock |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 2,068 | 4,136 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 2,068 | 2,218 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Richa Poddar | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 725 | 1,493 (0%) | 0% | 31.4 | 22,783 | Common stock |